Aytu BioPharma Inc. (AYTU)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN Summary
New Strong Sell Stocks for July 16th
AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.
Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.2 per share a year ago.
Aytu BioPharma Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 2 | $5.46 | $4.6 | -$0.86 | -15.75% |
 Christopher C. Powers Farther Finance Advisors, LLC | 4 | $9 | $8.92 | -$0.08 | -0.89% |
 Zachary Canonico DIADEMA PARTNERS LP | 353,077 | $727,825.77 | $787,361.71 | $59,535.94 | 8.18% |
 Yuen Man Lee Persistent Asset Partners Ltd. | 37,984 | $95,083.04 | $89,642.24 | -$5,440.8 | -5.72% |
Aytu BioPharma Inc. (AYTU) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aytu BioPharma Inc. ever had a stock split?
Aytu BioPharma Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Joshua R. Disbrow CEO | NASDAQ (CM) Exchange | 054754858 CUSIP |
| US Country | 83 Employees | - Last Dividend | 6 Jan 2023 Last Split | 1 Feb 2017 IPO Date |
Overview
Aytu Biopharma, Inc. is a commercial-stage pharmaceutical company that directs its efforts towards the commercialization of novel therapeutics and consumer healthcare products across the United States and internationally. Operating under two main segments, Rx and Consumer Health, Aytu Biopharma aims at addressing a variety of medical conditions through its diverse product portfolio. Initially known as Aytu BioScience, Inc., the company underwent a name change to Aytu Biopharma, Inc. in March 2021, marking a new phase in its business journey. Based in Denver, Colorado, Aytu Biopharma is committed to improving patient care by offering innovative solutions across different areas of healthcare, including ADHD treatments, allergic conditions, dietary supplements, and treatment for hair loss, among others.
Products and Services
- Adzenys XR-ODT & Cotempla XR-ODT
Prescription products targeted at treating attention deficit hyperactivity disorder (ADHD). Adzenys XR-ODT is designed for patients six years and older, while Cotempla XR-ODT caters to patients aged six to seventeen years old.
- Karbinal ER, Poly-Vi-Flor, and Tri-Vi-Flor
These are part of the pediatric prescription product portfolio. Karbinal ER is an extended-release suspension formulated to treat various allergic conditions in patients two years and above. Poly-Vi-Flor and Tri-Vi-Flor are complementary prescription fluoride-based multi-vitamin products. They come in liquid and chewable tablet forms, designed for infants and children suffering from fluoride deficiency.
- Regoxidine - for Men and Women
An over-the-counter aerosol foam developed as a proprietary solution for treating hair loss in both men and women.
- OmepraCareDR and EsomepraCareDR
These products represent Aytu Biopharma’s offerings in the digestive health category, specifically targeting frequent heartburn. They are acid reducers available over-the-counter.
- AR101 (enzastaurin)
Currently in development, AR101 is an investigational first-in-class small molecule, serine/threonine kinase inhibitor. It aims at targeting the treatment of vascular Ehlers-Danlos Syndrome through an orally available medication.
